Pesquisar
vTv Therapeutics Inc
VTVTAdicionar à lista de desejos
38.430USD
+6.765+21.36%
Fechamento 05/14, 16:00（ET）Cotações atrasadas em 15 min
151.37MValor de mercado
PerdaP/L TTM
Mais detalhes de vTv Therapeutics Inc Empresa
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Informações de vTv Therapeutics Inc
Código da empresaVTVT
Nome da EmpresavTv Therapeutics Inc
Data de listagemJul 30, 2015
CEOSekhri (Paul Jai)
Número de funcionários23
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 30
Endereço3980 Premier Dr
CidadeHIGH POINT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27265
Telefone13368410300
Sitehttps://vtvtherapeutics.com/
Código da empresaVTVT
Data de listagemJul 30, 2015
CEOSekhri (Paul Jai)
Executivos da empresa vTv Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
4.82K
+61.94%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
Mr. Daniel (Dan) Spiegelman
Mr. Daniel (Dan) Spiegelman
Director
Director
--
--
Dr. Michael Tung, M.D.
Dr. Michael Tung, M.D.
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
4.82K
+61.94%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
FY2023
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: dom, 10 de mai
Atualizado em: dom, 10 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
MacAndrews & Forbes Holdings, Inc.
37.83%
Samsara BioCapital, LLC
7.58%
Fidelity Management & Research Company LLC
6.83%
Trails Edge Capital Partners LP
5.86%
Millennium Management LLC
5.71%
Outro
36.18%
Investidores
Investidores
Proporção
MacAndrews & Forbes Holdings, Inc.
37.83%
Samsara BioCapital, LLC
7.58%
Fidelity Management & Research Company LLC
6.83%
Trails Edge Capital Partners LP
5.86%
Millennium Management LLC
5.71%
Outro
36.18%
Tipos de investidores
Investidores
Proporção
Holding Company
37.83%
Investment Advisor
20.61%
Hedge Fund
9.98%
Venture Capital
7.58%
Individual Investor
1.15%
Investment Advisor/Hedge Fund
1.13%
Family Office
0.16%
Research Firm
0.15%
Outro
21.41%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
47
1.41M
35.82%
+186.91K
2025Q4
44
1.18M
30.04%
+255.03K
2025Q3
47
1.15M
29.13%
+562.26K
2025Q2
54
1.51M
57.66%
-17.51K
2025Q1
53
1.53M
60.03%
+1.63K
2024Q4
55
1.51M
61.92%
-7.51K
2024Q3
55
1.49M
61.31%
+181.69K
2024Q2
53
1.29M
53.13%
+308.00
2024Q1
64
1.68M
72.07%
+129.32K
2023Q4
64
1.40M
68.78%
-52.49K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
MacAndrews & Forbes Holdings, Inc.
912.98K
23.18%
--
--
Apr 01, 2025
Samsara BioCapital, LLC
298.50K
7.58%
-75.97K
-20.29%
Dec 31, 2025
Fidelity Management & Research Company LLC
268.86K
6.83%
+75.97K
+39.38%
Dec 31, 2025
Trails Edge Capital Partners LP
231.00K
5.86%
--
--
Dec 31, 2025
Invus Public Equities Advisors, LLC
163.00K
4.14%
--
--
Dec 31, 2025
Baker Bros. Advisors LP
148.31K
3.77%
--
--
Dec 31, 2025
Geode Capital Management, L.L.C.
28.19K
0.72%
+12.90K
+84.30%
Dec 31, 2025
683 Capital Management LLC
18.27K
0.46%
+18.27K
--
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proporção0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Data
Data ex-dividendo
Tipo
Proporção
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
